Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting USP47 enhances the efficacy of KRAS inhibitor in KRASG12C mutated non-small cell lung cancer by controlling deubiquitination of c-Myc.

Pharmacological research - 1 May 2025

Shin Hyungkyung, Hwang SuA, Jeong Jeong Hyun, Shin Sang Chul, Oh Yeonji, Kim Jinhyeok, Hwang Inah, Kim Eunice EunKyeong, Choo Hyunah, Song Eun Joo

Abstract excerpt

FDA-approved KRASG12C inhibitors, like Sotorasib, target G12C-mutated KRAS in NSCLC. However, issues with insensitivity and drug resistance have emerged, requiring the development of new combination therapies to overcome these limitations. USP47 has been identified as a regulator of cancer-related signaling pathways such as Wnt, Hippo, and p53. However, its role in the KRAS signaling pathway remains largely...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Mice, Nude
Share to Piperazines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Proto-Oncogene Proteins c-myc

Share to Proto-Oncogene Proteins p21(ras)

Share to Pyridines

Share to Pyrimidines

Share to Ubiquitin Thiolesterase

Share to Ubiquitination

Source

Identifiers

PMID: 40180254
DOI: 10.1016/j.phrs.2025.107722

Genes

USP47
KRAS
USP7

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting USP47 enhances the efficacy of KRAS inhibitor in KRASG12C mutated non-small cell lung cancer by controlling deubiquitination of c-Myc.PMID 40180254Read ↗

USP7 deubiquitinates KRAS and promotes non-small cell lung cancer.Semantic proximity Read ↗

Oncogenic KRAS effector USP13 promotes metastasis in non-small cell lung cancer through deubiquitinating β-catenin.Semantic proximity Read ↗

USP39 Deubiquitinase Is Essential for KRAS Oncogene-driven Cancer.Semantic proximity Read ↗

USP14 Inhibition Regulates Tumorigenesis by Inducing Autophagy in Lung Cancer In VitroSemantic proximity Read ↗

USP48 stabilizes YBX1 to enforce a Wnt-driven stemness circuit and osimertinib resistance in EGFR-mutant NSCLC.Semantic proximity Read ↗

USP10 as a Potential Therapeutic Target in Human CancersSemantic proximity Read ↗

USP28 deletion and small molecule inhibition destabilises c-Myc and elicits regression of squamous cell lung carcinomaSemantic proximity Read ↗

Deubiquitinase USP18 Loss Mislocalizes and Destabilizes KRAS in Lung Cancer.Semantic proximity Read ↗

Over-Expression of Deubiquitinating Enzyme USP14 in Lung Adenocarcinoma Promotes Proliferation through the Accumulation of β-CateninSemantic proximity Read ↗

The USP10-HDAC6 axis confers cisplatin resistance in non-small cell lung cancer lacking wild-type p53.Semantic proximity Read ↗

USP53 promotes apoptosis and inhibits glycolysis in lung adenocarcinoma through FKBP51‐AKT1 signalingSemantic proximity Read ↗

Targeting USP13 ‐mediated drug tolerance increases the efficacy of EGFR inhibition of mutant EGFR in non‐small cell lung cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.